Emergency Medical Treatment Information
Clementia Announces Symposium at the 8th International Conference on Children's Bone Health (ICCBH)
An important announcement from Clementia
Clementia Announces Preliminary Results of its Phase 2 Trial in Treatment of FOP
An important announcement from Clementia
The IFOPA is pleased to share this announcement from Clementia Pharmaceuticals: Top-line Results from Phase 2 Trial of Palovarotene for Treatment of Patients with FOP. Read more.
Dr. Fred Kaplan To Receive NORD's Rare Impact Award
The National Organization for Rare Disorders (NORD) named Dr. Fred Kaplan among its 2017 honorees.
Regeneron Shares Updates on its Ongoing FOP Research Program
Potentially Promising Treatment for FOP
We are pleased to share a few exciting updates on our ongoing work to help improve the lives of people with FOP.
Bipartisan Support
21st Century Cures Legislation Signed by President Obama
On December 7, the Senate followed the House of Representative's lead and signed the 21st Century Cures bill which is focused on developing treatments and cures for rare diseases; President Obama signed it on December 13.
Three new Clementia sites now open for Part B of the Phase 2 Open-label Extension Trial
Approval of 3 New Sites!
The participation of individuals living with FOP in clinical studies and trials is key to FOP drug development efforts.
Join the IFOPA and Clementia for an Important Webinar
Phase 2 Trial Webinar
We hope you’ll join us Wednesday, Nov. 30, 2016, 11 am to noon Eastern Time, for an important webinar presented by Clementia on the top-line results from the phase 2 trial of palovarotene for treatment of patients with fibrodysplasia ossificans progressiva.
Opportunity for New Patients to Enroll in Palovarotene Study
Please read Clementia's Clinical Program Announcement: Opportunity for New Adult and Older Adolescent Subjects to Enroll in Palovarotene Study. Click here.
Regeneron's Work in FOP
The International FOP Association is pleased to share the following news from Regeneron Pharmaceuticals
Regeneron is pleased to inform you that anti-Activin A antibody, REGN2477, is now in a clinical trial.
A Remarkable Record of Service – And An Important Transition
Thank you for your commitment!
Still active in the FOP community, Dr. Pignolo has a accepted a new position.
